Search results for "NF-"

showing 10 items of 461 documents

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

2020

Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most sign…

Drug targetAntineoplastic AgentsReviewCatalysisNF-κBdrug targetlcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundNeoplasmsMDRmedicineBiomarkers TumorcancerAnimalsHumansMolecular Targeted TherapyPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyTriple-negative breast cancerbusiness.industryOrganic ChemistryNF-kappa BCancerMyeloid leukemiaNF-κBGeneral Medicinemedicine.diseaseComputer Science ApplicationsMultiple drug resistanceClinical trialCell Transformation Neoplasticlcsh:Biology (General)lcsh:QD1-999chemistryDrug Resistance NeoplasmHepatocellular carcinomaCancer researchSettore BIO/14 - FarmacologiaDisease SusceptibilitybusinessInternational Journal of Molecular Sciences
researchProduct

Multifactorial nature of hepatocellular carcinoma drug resistance: Could plant polyphenols be helpful?

2007

Primary hepatocellular carcinoma (HCC) is a quite frequent tumor which results in high mortality and most often exhibits a poor response to present drug therapies. Clearly, a thorough understanding of the biological bases of this malignancy might suggest new strategies for its treatment. Here we examine the evidences that both "pharmacological" mechanisms (e.g. drug transporter or detoxification enzyme over-expression) and alterations in other critical factors, including the IAPs (Inhibitory of Apoptosis Proteins), involved in enhancement of cell survival and proliferation may determine the therapeutic resistance of HCC; we also underline the possible role in the process of the activation o…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectDrug transporterDrug resistancePharmacologyBiologyMalignancyNF-κBInhibitor of Apoptosis ProteinsPlant polyphenolsPhenolsmedicineHumansInhibition of cell deathTopic HighlightsTranscription factorSensitizationmedia_commonFlavonoidsLiver NeoplasmsNF-kappa BGastroenterologyPolyphenolsGeneral MedicineIAPmedicine.diseaseNFKB1medicine.anatomical_structureDrug Resistance NeoplasmApoptosisDrug resistanceHepatocellular carcinomaCancer researchPlant PreparationsPhytotherapyWorld Journal of Gastroenterology
researchProduct

The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-κB) pathway by targeting RelA/p65.

2015

Infection with human cytomegalovirus (HCMV) is a serious medical problem, particularly in immunocompromised individuals and neonates. The success of standard antiviral therapy is hampered by low drug compatibility and induction of viral resistance. A novel strategy is based on the exploitation of cell-directed signaling inhibitors. The broad antiinfective drug artesunate (ART) offers additional therapeutic options such as oral bioavailability and low levels of toxic side-effects. Here, novel ART-derived compounds including dimers and trimers were synthesized showing further improvements over the parental drug. Antiviral activity and mechanistic aspects were determined leading to the followi…

DrugHuman cytomegalovirusTranscriptional Activationmedia_common.quotation_subjectTranscription Factor RelAArtesunateCytomegalovirusPharmacologyCREBAntiviral Agentschemistry.chemical_compoundVirologyDrug Resistance ViralmedicineHumansCyclic AMP Response Element-Binding ProteinHerpesviridaemedia_commonPharmacologybiologyHEK 293 cellsNF-kappa BTranscription Factor RelANF-κBmedicine.diseaseIn vitroArtemisininsUp-RegulationHEK293 CellschemistryMutationbiology.proteinSignal transductionSignal TransductionAntiviral research
researchProduct

Commentary. Regulation of drug and immune resistance by YY1 in cancer.

2010

DrugYY1business.industrymedia_common.quotation_subjectImmune resistanceCancermedicine.diseaseBiochemistryDrug resistance YY1 NF-kB artesunateImmunologyGeneticsmedicineSettore BIO/14 - FarmacologiaMolecular MedicinebusinessBiotechnologymedia_common
researchProduct

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhi…

2014

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivati…

EXPRESSIONMyeloidCancer ResearchPathologymedicine.medical_specialtyMyeloidCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression Profiling; Hematology; Cancer Research; Anesthesiology and Pain MedicineAcuteBiologyCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression ProfilingDendritic CellArticleMALIGNANCIESMULTIPLE-MYELOMABlastic plasmacytoid dendritic cell neoplasmBlastic plasmacytoid dendritic cell neoplasm; anti-NF-kB-treatment; GEPGene expressionmedicineHumansNeoplasmanti-NF-kB-treatmentGene Expression ProfilingCell CycleNF-kappa BleukemiaIN-VITRODendritic CellsHematologyBlastic plasmacytoid dendritic cell neoplasmmedicine.diseaseCANCERGEPFACTOR-KAPPA-BLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUEDIFFERENTIATIONAnesthesiology and Pain Medicinemedicine.anatomical_structureLYMPHOID PATHWAYSOncologyCell cultureHEMATODERMIC NEOPLASMImmunohistochemistryCellular modelEx vivoHumanSignal Transduction
researchProduct

Therapeutic administration of 3,4,5-trimethoxy-4'-fluorochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-in…

2003

We have previously investigated the effects of a series of dimethoxy- and trimethoxychalcone derivatives, with various patterns of fluorination, on nitric oxide production in LPS-stimulated murine RAW 264.7. The present study was designed to determine if 3,4,5-trimethoxy-4'-fluorochalcone (CH 17) could modulate the production of NO and/or prostaglandins in vivo. On the mouse macrophage cell line RAW 264.7 CH 17 inhibited dose-dependently NO production, with an IC(50) value in the nanomolar range, and reduced PGE(2) levels by a 58% at 10 microM. This compound had no direct inhibitory effect on iNOS and COX-2 activities. NO reduction was the consequence of inhibition of the expression of iNOS…

ElectrophoresisMaleBlotting WesternNitric Oxide Synthase Type IIArthritisPharmacologyNitric OxideMonocytesNitric oxideMicechemistry.chemical_compoundChalconeChalconesIn vivoOral administrationmedicineAnimalsHumansEnzyme InhibitorsProstaglandin E2IC50Cells CulturedPharmacologyDose-Response Relationship DrugNF-kappa BMembrane ProteinsGeneral Medicinemedicine.diseaseArthritis ExperimentalIn vitroRatsIsoenzymesDose–response relationshipBiochemistrychemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesRats Inbred LewCyclooxygenase 1Nitric Oxide Synthasemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants.

1998

Although nitric oxide (NO) and antioxidants inhibit adhesion molecule expression, their inhibitory effects on nuclear factor kappaB (NF-kappaB) activation may differ. The NO donors, but not 8-bromo-cGMP, decreased tumor necrosis factor alpha (TNF-alpha)-induced VCAM-1, ICAM-1, and E-selectin expression by 11-70%. In contrast, NAC completely abolished VCAM-1 and E-selectin expression and decreased ICAM-1 expression by 56%. Gel shift assays demonstrate that NF-kappaB activation was inhibited by both NO and antioxidants. The activation of NF-kappaB involves the phosphorylation and degradation of its cytoplasmic inhibitor IkappaB-alpha by 26S proteasomes. The 26S proteasome inhibitor MG132 prev…

EndotheliumImmunologyVascular Cell Adhesion Molecule-1IκB kinaseBiologyProtein Serine-Threonine KinasesNitric OxideAntioxidantsNitric oxidechemistry.chemical_compoundMiceNF-KappaB Inhibitor alphaMG132medicineImmunology and AllergyAnimalsHumansPromoter Regions GeneticCells CulturedI-Kappa-B KinaseNF-kappa BCell BiologyIntercellular Adhesion Molecule-1Molecular biologyI-kappa B KinaseDNA-Binding Proteinsmedicine.anatomical_structurechemistryProteasomePhosphorylationTumor necrosis factor alphaI-kappa B ProteinsEndothelium VascularE-SelectinCell Adhesion MoleculesJournal of leukocyte biology
researchProduct

Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte–endothelial cell interactions

2015

AbstractEnhanced leukocyte recruitment is an inflammatory process that occurs during early phases of the vascular dysfunction that characterises atherosclerosis. We evaluated the impact of anti-TNF-α (adalimumab, infliximab and etanercept) and anti-IL-12/23 (ustekinumab) on interactions between human leukocytes and endothelial cells in a flow chamber that reproduced in vivo conditions. Clinical concentrations of anti-TNF-α were evaluated on the leukocyte recruitment induced by a variety of endothelial (TNF-α, interleukin-1β, lymphotoxin-α and angiotensin-II) and leukocyte (PAF, IL-12 and IL-23) stimuli related to inflammation and atherosclerosis. Treatment with anti-TNF-α, even before or af…

EndotheliumInflammationAnti-IL-12/23 agentsCardiovascular side effectsBiologicsInterleukin-23Rheumatic diseasesIn vivoPsoriasisHuman Umbilical Vein Endothelial CellsInterleukin 23HumansMedicineAnti-TNF-α agentsPharmacologyTumor Necrosis Factor-alphabusiness.industryCell adhesion moleculeAdalimumabEndothelial Cellsmedicine.diseaseInterleukin-12Leukocyte–endothelial cell interactionsEndothelial stem cellmedicine.anatomical_structureImmunologyLeukocytes MononuclearTumor necrosis factor alphamedicine.symptombusinessEuropean Journal of Pharmacology
researchProduct

Extracellular Hsp70 Enhances Mesoangioblast Migration via an Autocrine Signaling Pathway

2016

Mouse mesoangioblasts are vessel-associated progenitor stem cells endowed with the ability of multipotent mesoderm differentiation. Therefore, they represent a promising tool in the regeneration of injured tissues. Several studies have demonstrated that homing of mesoangioblasts into blood and injured tissues are mainly controlled by cytokines/chemokines and other inflammatory factors. However, little is known about the molecular mechanisms regulating their ability to traverse the extracellular matrix (ECM). Here, we demonstrate that membrane vesicles released by mesoangioblasts contain Hsp70, and that the released Hsp70 is able to interact by an autocrine mechanism with Toll-like receptor …

Extracellular VesicleNF-kappa BEndothelial CellsModels BiologicalHsp70Toll-Like Receptor 4Autocrine CommunicationMicePhosphatidylinositol 3-KinasesMembrane MicrodomainsMatrix Metalloproteinase 9NF-KappaB Inhibitor alphaCell MovementMesoangioblast Stem CellAnimalsMatrix Metalloproteinase 2HSP70 Heat-Shock ProteinsExtracellular SpaceMatrix MetalloproteinaseProto-Oncogene Proteins c-aktLow Density Lipoprotein Receptor-Related Protein-1MigrationProtein BindingSignal Transduction
researchProduct

Beneficial Effect of Shikonin on Experimental Colitis Induced by Dextran Sulfate Sodium in Balb/C Mice

2012

[EN] The naphthoquinone shikonin, a major component of the root of Lithospermum erythrorhizon, now is studied as an anti-inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/C mice by oral administration of 5% dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower in shikonin-treated mice than in the colitic group, as well as the…

FarmacologiaArticle SubjectPolymorphonuclear leukocytesNF-KAPPA-BActivationIntestinal inflammationPharmacologyInflammatory bowel diseaseBALB/cchemistry.chemical_compoundExperimental Murine ColitisOral administrationWeight lossInflammatory-bowel-diseasemedicineAntisense oligonucleotideAcid-induced colitisbiologybusiness.industrylcsh:Other systems of medicineLithospermum erythrorhizonbiology.organism_classificationNFKB1medicine.diseaselcsh:RZ201-999Ulcerative colitisNaphthoquinoneComplementary and alternative medicinechemistryUlcerative-colitisImmunologyCytokinesmedicine.symptombusinessAntiinflamatorisResearch ArticleEvidence-Based Complementary and Alternative Medicine
researchProduct